ArticleScientific reports2025
Comparison of risk factors and outcomes of raised vs normal cardiac troponin levels in COVID-19 patients: a retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 primarily affects the lungs, but it can also cause neurological, psychological, and cardiovascular complications. Myocardial injury and myocarditis are of significant concerns that are often indicated by elevated troponin levels, a marker of cardiac involvement. This study analyzed risk factors and outcome of elevated troponin-I levels in COVID-19 patients compared to those with normal levels. We included 766 COVID-19 patients of which 50.6% were female, and 74.2% having co-morbidities. Patients were divided into two groups: 383 with elevated troponin levels and 383 with normal levels. We compared their demographics, clinical characteristics and outcome to identify the risk factors for cardiac injury during COVID-19 infection. Data was analyzed through SPSS V.24. Patients with elevated troponin were predominantly male (63.7%) and younger (mean age 58.42 years) than those with normal levels (64.86 years). Despite having fewer co-morbidities and milder COVID-19 cases, participants with raised troponin had lower ICU admission (37.02% vs. 60.2%) and ARDS rates (38.78% vs. 61.2%), yet mortality rates were similar. Ejection fraction remained stable across groups, but Pro-BNP levels were significantly lower in those with raised troponin (8.4% vs. 91.5%). This study highlights significant associations between elevated troponin levels in COVID-19 patients and factors like male gender, comorbid conditions, and ARDS. However, contrary to other studies, higher troponin levels were often found in patients with less severe COVID-19 with negative association with pro-BNP levels. The findings suggest that elevated troponin in COVID-19 does not directly correlate with disease severity or mortality. Further research with longitudinal follow-up and more granular biomarker analysis is recommended to fully elucidate the relationship between troponin levels and cardiac outcomes in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.